The emerging role of tacrolimus in myasthenia gravis

Conclusions:
There is limited yet promising information to suggest a beneficial role for tacrolimus in reducing QMGS and corticosteroid burden in patients with refractory symptoms or new-onset MG. Long-term use appears to be safe in this population.

Source: Therapeutic Advances in Neurological Disorders - March 10, 2015 Category: Neurology Authors: Cruz, J. L., Wolff, M. L., Vanderman, A. J., Brown, J. N. Tags: Reviews Source Type: research